参考文献/References:
[1] KINOSHITA J,FUSHIDA S,HARADA S,et al. Local angiotensin Ⅱ-generation in human gastric cancer:correlation with tumor progression through the activation of ERK1/2,NF-kappaB and surviving[J]. Int J Oncol,2009,34(6):1 573-1 582.
[2]PUDDEFOOT J R,UDEOZO U K I,BARKER S,et al. The role of angiotensin Ⅱ in the regulation of breast cancer cell adhesion and invasion[J]. Endocrine-related cancer,2006,13:895-903.
[3]SUGANUMA T,INO K,SHIBATA K,et al. Functional expression of the angiotensin Ⅱ type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion,angiogenesis,and peritoneal dissemination[J]. Clin Cancer Res,2005,11(7):2 686-2 694.
[4]OH E,KIM J Y,CHO Y,et al. Over-expression of angiotensin Ⅱ type 1 receptor in breast cancer cells induces epithelial-mesenchymal transition and promotes tumor growth and angiogenesis[J]. Biochim Biophys Acta,2016,1863(6 Pt A):1 071-1 081.
[5]FUJIHARA S,MORISHITA A,OGAWA K,et al. The angiotensin Ⅱ type 1 receptor antagonist telmisartan inhibits cell proliferation and tumor growth of esophageal adenocarcinoma via the AMPKa/mTOR pathway in vitro and in vivo[J]. Oncotarget,2017,8(5):8 536-8 549.
[6]CHEN X,MENG Q,ZHAO Y,et al. Angiotensin Ⅱ type 1 receptor antagonists inhibit cell proliferation and angiogenesis in breast cancer[J]. Cancer Lett,2013,328(2):318-324.
[7]GUO R,GU J,ZHANG Z,et al. MicroRNA-410 functions as a tumor suppressor by targeting angiotensin Ⅱ type 1 receptor in pancreatic cancer[J]. IUBMB Life,2015,67(1):42-53.
[8]FOEKENS J A,PETERS H A,LOOK M P,et al. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients[J]. Cancer Res,2000,60(3):636-643.
[9]王学谦,林洪生. uPA/uPAR与恶性肿瘤关系的研究进展[J]. 医学研究杂志,2016,45(9):16-17.
[10]SALEHI A H,XANTHOUDAKIS S,BARKER P A. NRAGE,a p75 neurotrophin receptor interacting protein,induces caspase activation and cell death through a JNK dependent mitochondrial pathway[J]. J Biol Chem,2002,277(50):48 043-48 050.
[11]CHU,C S,CHU C S,XUE B,et al. NRAGE suppresses metastasis of melanoma and pancreatic cancer in vitro and in vivo[J]. Cancer Lett,2007,250(2):268-275.
[12]STILLFRIED G E,SAUNDERS D N,RANSON M. Plasminogen binding and activation at the breast cancer cell surface:the integral role of urokinase activity[J]. Breast Cancer Res,2007,9(1):R14.
[13]WANG Y X,MARTIN-MCNULTY B,FREAY A D,et al. Angiotensin Ⅱ increases urokinase-type plasminogen activator expression and induces aneurysm in the abdominal aorta of apolipoprotein E-deficient mice[J]. Am J Pathol,2001,159(4):1 455-1 464.
[14]RODRIGUES-FERREIRA S R,ABDELKARIM M,DILLENBURG-PILLA P,et al. Angiotensin Ⅱ facilitates breast cancer cell migration and metastasis[J]. PLoS ONE,2012,7(4):e35667.
[15]PUDDEFOOT J R,UDEOZO U K I,BARKER S,et al. The role of angiotensin Ⅱ in the regulation of breast cancer cell adhesion and invasion[J]. Endocrine-related cancer,2006,13:895-903.
[16]PENAFUERTE C A,GAGNON B,SIROIS J,et al. Identification of neutrophil-derived proteases and angiotensin Ⅱ as biomarkers of cancer cachexia[J]. Br J Cancer,2016,114(6):680-687.
[17]SHIMIZU D,KANDA M,SUGIMOTO H,et al. NRAGE promotes the malignant phenotype of hepatocellular carcinoma[J]. Oncology Lett,2016,11:1 847-1 854.